I would appreciate a clarification on this one. As I said, my patents knowledge stinks.
- They're receiving patents on the use of someone else's compounds in a specific indication?
- If they have a novel compound with its own IP, why do they need use patents of baricitinib / juxolitinib? Is it in an attempt to block the latter two from being used in that indication?
- Incyte is moving ahead with a topical formulation in this indication. Is that due to these patent applications?
Market Data 
Markets 
AI
